Christopher Gibson's Insider Trades & SAST Disclosures
Christopher Gibson's most recent trade in Recursion Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 36,197 Class A Common Stock done at an average price of $4.2 . Disclosure was reported to the exchange on May 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher Gibson.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.25 per share. | 15 May 2025 | 36,197 | 1,081,253 | - | 4.2 | 153,837 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 27 Mar 2025 | 138,574 | 1,117,450 | - | 6.0 | 836,987 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Mar 2025 | 20,000 | 1,276,024 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Mar 2025 | 20,000 | 5,896,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Mar 2025 | 20,000 | 5,916,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.37 per share. | 05 Mar 2025 | 20,000 | 1,256,024 | - | 6.4 | 127,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Mar 2025 | 20,000 | 1,276,024 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.58 per share. | 05 Mar 2025 | 20,000 | 1,256,024 | - | 6.6 | 131,600 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.64 per share. | 18 Feb 2025 | 17,132 | 1,256,024 | - | 10.6 | 182,284 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Feb 2025 | 20,000 | 1,293,156 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Feb 2025 | 20,000 | 5,936,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Feb 2025 | 20,000 | 5,956,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.12 per share. | 05 Feb 2025 | 20,000 | 1,273,156 | - | 8.1 | 162,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Feb 2025 | 20,000 | 1,293,156 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.68 per share. | 05 Feb 2025 | 20,000 | 1,273,156 | - | 7.7 | 153,600 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 1,050,567 | 1,050,567 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 525,283 | 1,261,916 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 16,809 | 1,278,725 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.25 per share. | 03 Feb 2025 | 5,569 | 1,273,156 | - | 7.2 | 40,375 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 08 Jan 2025 | 20,000 | 756,633 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.31 per share. | 08 Jan 2025 | 20,000 | 736,633 | - | 7.3 | 146,200 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 08 Jan 2025 | 20,000 | 756,633 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.05 per share. | 08 Jan 2025 | 20,000 | 736,633 | - | 7.1 | 141,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 08 Jan 2025 | 20,000 | 5,996,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 08 Jan 2025 | 20,000 | 5,976,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 04 Dec 2024 | 20,000 | 756,633 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 04 Dec 2024 | 20,000 | 6,016,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 04 Dec 2024 | 20,000 | 6,036,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.12 per share. | 04 Dec 2024 | 20,000 | 736,633 | - | 7.1 | 142,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 04 Dec 2024 | 20,000 | 756,633 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.16 per share. | 04 Dec 2024 | 20,000 | 736,633 | - | 7.2 | 143,200 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.17 per share. | 15 Nov 2024 | 26,023 | 736,633 | - | 6.2 | 160,692 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 13 Nov 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 13 Nov 2024 | 20,000 | 6,056,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 13 Nov 2024 | 20,000 | 6,076,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.35 per share. | 13 Nov 2024 | 20,000 | 762,656 | - | 7.4 | 147,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 13 Nov 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.74 per share. | 13 Nov 2024 | 20,000 | 762,656 | - | 7.7 | 154,800 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 02 Oct 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.08 per share. | 02 Oct 2024 | 20,000 | 762,656 | - | 6.1 | 121,600 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 02 Oct 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.16 per share. | 02 Oct 2024 | 20,000 | 762,656 | - | 6.2 | 123,200 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 02 Oct 2024 | 20,000 | 6,096,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 02 Oct 2024 | 20,000 | 6,116,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.14 per share. | 04 Sep 2024 | 20,000 | 762,656 | - | 6.1 | 122,800 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 04 Sep 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 04 Sep 2024 | 20,000 | 762,656 | - | 6.0 | 120,800 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 04 Sep 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 04 Sep 2024 | 20,000 | 6,136,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 04 Sep 2024 | 20,000 | 6,156,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 30 Aug 2024 | 5,000 | 762,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 5,000 | 282,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 29 Aug 2024 | 5,000 | 757,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2024 | 5,000 | 287,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 28 Aug 2024 | 5,000 | 752,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2024 | 5,000 | 292,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Aug 2024 | 5,000 | 747,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2024 | 5,000 | 297,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 5,000 | 302,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 26 Aug 2024 | 5,000 | 742,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2024 | 5,000 | 307,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 23 Aug 2024 | 5,000 | 737,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.69 per share. | 15 Aug 2024 | 26,082 | 732,656 | - | 6.7 | 174,489 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 07 Aug 2024 | 30,000 | 788,738 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 07 Aug 2024 | 30,000 | 6,196,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.10 per share. | 07 Aug 2024 | 30,000 | 758,738 | - | 7.1 | 213,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 07 Aug 2024 | 20,000 | 6,176,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.50 per share. | 07 Aug 2024 | 20,000 | 758,738 | - | 6.5 | 130,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 07 Aug 2024 | 20,000 | 778,738 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 10 Jul 2024 | 50,000 | 6,226,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 10 Jul 2024 | 50,000 | 6,276,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.47 per share. | 10 Jul 2024 | 50,000 | 758,738 | - | 7.5 | 373,500 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 10 Jul 2024 | 50,000 | 808,738 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.48 per share. | 10 Jul 2024 | 50,000 | 758,738 | - | 7.5 | 374,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 10 Jul 2024 | 50,000 | 808,738 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Jul 2024 | 25,000 | 758,738 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Jun 2024 | 100,000 | 6,326,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Jun 2024 | 100,000 | 908,738 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.00 per share. | 05 Jun 2024 | 50,000 | 708,738 | - | 9 | 450,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.42 per share. | 05 Jun 2024 | 50,000 | 758,738 | - | 8.4 | 421,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Jun 2024 | 25,000 | 833,738 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 05 Jun 2024 | 25,000 | 6,401,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Jun 2024 | 25,000 | 808,738 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 15 May 2024 | 26,082 | 808,738 | - | 10.0 | 261,081 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.73 per share. | 01 May 2024 | 50,000 | 863,524 | - | 7.7 | 386,500 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.47 per share. | 01 May 2024 | 28,704 | 834,820 | - | 8.5 | 243,123 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 01 May 2024 | 25,000 | 913,524 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 01 May 2024 | 21,296 | 6,426,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.47 per share. | 01 May 2024 | 21,296 | 834,820 | - | 8.5 | 180,377 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 01 May 2024 | 21,296 | 856,116 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.02 per share. | 03 Apr 2024 | 40,000 | 938,524 | - | 9.0 | 360,800 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.84 per share. | 03 Apr 2024 | 40,000 | 978,524 | - | 8.8 | 353,600 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2024 | 25,000 | 1,018,524 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 03 Apr 2024 | 25,000 | 486,000 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 03 Apr 2024 | 25,000 | 67,875 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.02 per share. | 03 Apr 2024 | 25,000 | 0 | - | 9.0 | 225,500 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 03 Apr 2024 | 25,000 | 25,000 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.84 per share. | 03 Apr 2024 | 25,000 | 0 | - | 8.8 | 221,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 03 Apr 2024 | 25,000 | 25,000 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.10 per share. | 28 Mar 2024 | 40,000 | 1,043,524 | - | 10.1 | 404,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Mar 2024 | 25,000 | 1,083,524 | - | 0 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges